CiteFacts · FDA Drug Shortages · FDA source
Liraglutide Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Hikma Pharmaceuticals USA, Inc. | Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) | Available | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) | Available | 08/13/2026 |
| Meitheal Pharmaceuticals, Inc. | Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) | Available | 06/01/2026 |
| Meitheal Pharmaceuticals, Inc. | Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) | Limited Availability | 06/01/2026 |
| Novo Nordisk, Inc. | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) | Available | 08/17/2026 |
| Novo Nordisk, Inc. | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) | Available | 08/17/2026 |
| Novo Nordisk, Inc. | Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | Available | 08/17/2026 |
| Novo Nordisk, Inc. | Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) | Limited Availability | 08/17/2026 |
| Novo Nordisk, Inc. | Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) | Limited Availability | 08/17/2026 |
| Teva Pharmaceuticals USA, Inc. | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) | Not stated | 05/14/2026 |
Source facts
Grouped generic ingredient: Liraglutide Injection · 10 package records · Latest FDA row update: 08/17/2026
Therapeutic categories: Endocrinology/Metabolism
Dosage forms: Injection
Routes: SUBCUTANEOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.